Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 158 of 158 results for urinary tract infections

  1. Magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids (HTG12)

    Evidence-based recommendations on magnetic resonance (MR) image-guided percutaneous laser ablation of uterine fibroids. This involves passing laser heat through needles inserted into the fibroid to destroy it.

    HealthTech guidance
    Published
    17 December 2003
    View recommendations

    Sections for HTG12

  2. Bone-anchored cystourethropexy (HTG6)

    Evidence-based recommendations on bone-anchored cystourethropexy for treating stress urinary incontinence in women. Bone-anchored cystourethropexy is a minimally invasive bladder neck needle suspension procedure.

    HealthTech guidance
    Published
    26 November 2003
    View recommendations

    Sections for HTG6

  3. Urinary tract infection

    All NICE products on urinary tract infection. Includes any guidance, advice and quality standards.

    Topic page

  4. UroShield for preventing catheter-associated urinary tract infections (MTG69)

    We have moved Medical technologies guidance 69 to become HealthTech guidance 620. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  5. Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessment (HTE7)

    We have moved Health technology evaluation 7 to become HealthTech guidance 674. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.

    Withdrawn guidance

  6. Multidrug resistant urinary tract infections: fosfomycin trometamol (ESUOM17)

    This evidence summary has been withdrawn because a product containing fosfomycin trometamol with a marketing authorisation for treating multidrug resistant urinary tract infections is now available in the UK.

    Withdrawn advice

  7. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  8. Urinary tract infection in under 16s: diagnosis and management (CG54)

    This guidance has been updated and replaced by NICE guideline NG224.

    Withdrawn guideline